ArticleJournal of cardiothoracic surgery2018
Neutrophil-lymphocyte ratio predicts recurrence in patients with resected stage 1 non-small cell lung cancer.
Article in Journal of cardiothoracic surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05432739 (Nodule IMmunophenotyping Biomarker for Lung Cancer Early Diagnosis Study), which is not on this map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Nodule IMmunophenotyping Biomarker for Lung Cancer Early Diagnosis Study
Who cites it
28 citing papers in PubMed.
- CT-derived abdominal organ volumetrics for predicting recurrence-free and disease-free survival in resected non-small cell lung cancer: a multicenter retrospective cohort study.Translational lung cancer research · 2026Article
- Prognostic impact of preoperative immunenutritional indices in patients undergoing curative resection for non-small cell lung cancer: a retrospective analysis.Journal of thoracic disease · 2026Article
- Risk factors of up-Stage and lymph node metastasis for clinical stage IA3 non-small cell lung cancer.Journal of thoracic disease · 2025Article
- Site-Specific Inflammatory Signatures in Metastatic NSCLC: Insights from Routine Blood Count Parameters.Medicina (Kaunas, Lithuania) · 2025Article
- The relationship between blood biomarkers and prognosis of pathologic stage IA pure-solid non-small cell lung cancer patients.Journal of thoracic disease · 2025Article
- Prognostic Value of Systemic Immune Inflammation Index in Squamous Cell Lung Cancer.Journal of clinical medicine · 2025Article
- Accurate Selection of Sublobar Resection for Small Non-small Cell Lung Cancer.Annals of surgical oncology · 2025Article
- Prognostic Value of Tertiary Lymphoid Structures in Stage I Nonsmall Cell Lung Cancer: Does Location Matter?Clinical Medicine Insights. Oncology · 2025Article
- Postoperative short-term prognostic factors in patients with primary lung cancer who undergo lobectomy: a study on the prognostic predictors of early postoperative recurrence.Journal of thoracic disease · 2024Article
- Impact of the number of dissected lymph nodes on machine learning-based prediction of postoperative lung cancer recurrence: a single-hospital retrospective cohort study.BMJ open respiratory research · 2024Article
- Nonlinear association between PD-L1 expression levels and the risk of postoperative recurrence in non-small cell lung cancer.Scientific reports · 2024Article
- Article
- Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer.International journal of molecular sciences · 2023Review
- PD-L1 Expression is not a Predictive Factor for Recurrence in Resected Non-small Cell Lung Cancer.Lung · 2023Article
- Nomogram combining clinical and radiological characteristics for predicting the malignant probability of solitary pulmonary nodules measuring ≤ 2 cm.Frontiers in oncology · 2023Article
- Invasive area to tumor ratio is a significant prognostic factor for non-small cell lung cancer.Thoracic cancer · 2022Article
- Prognostic factors for long-term survival following complete resection by lobectomy in stage I non-small cell lung cancer.Thoracic cancer · 2022Article
- Pre-treatment immune status predicts disease control in NSCLCs treated with chemoradiation and durvalumab.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2022Article
- Dynamic perioperative variation of neutrophil-to-lymphocyte ratio as an independent prognosis factor following lobectomy for NSCLC.Updates in surgery · 2021Article
- Links between Inflammation and Postoperative Cancer Recurrence.Journal of clinical medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim was to determine the prognostic value of the neutrophil-lymphocyte ratio (NLR) in patients with completely resected stage 1 non-small cell lung cancer (NSCLC).
methodsThe study enrolled 382 NSCLC patients, and an optimal NLR cutoff value was determined by ROC analysis. Patients were divided by preoperative NLR into low (< 1.5, n = 99), intermediate (1.5 ≤ NLR < 3.5, n = 245), and high (NLR ≥ 3.5, n = 38) value groups. Serum diacron-reactive oxygen metabolites (d-ROMs) were assayed in 33 consecutive patients and used as an indicator of oxidative stress.
resultsThe mean NLR in patients with high d-ROMs (> 300 U.CARR, n = 16) was 1.72 ± 0.67, which was significantly higher than that in patients with low d-ROMs (1.41 ± 0.39, n = 17; P = 0.018). The 3-, 5- and 10-year survival rates in the three NLR groups were 92, 77, and 59% (low); 82, 70, and 50% (intermediate); and 76, 58, and 32% (high) (P = 0.034). The 1-, 3- and 5-year recurrence-free survival rates in the three groups were 98, 90, and 86% (low), 91, 77, and 74% (intermediate); and 92, 77, and 68% (high) (P = 0.033). Multivariate analysis found that although NLR was not predictive of overall survival, high NLR was an independent risk factor of recurrence (hazard ratio: 2.03, 95% confidence interval: 1.17-3.79, P = 0.011) as were as age, pathological stage, tumor differentiation, and lymph-vascular invasion.
conclusionsA low preoperative NLR predicted good prognosis, and was associated with low systemic inflammation status in patients with stage 1 NSCLC. It may be helpful when considering intervals of routine follow-up or choice of adjuvant therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.